Navigation Links
InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
Date:1/4/2012

BRISBANE, Calif., Jan. 4, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will report unaudited fourth quarter 2011 revenue related to sales of Esbriet® (pirfenidone) in Germany, as well as other metrics related to the Esbriet launch, prior to the open of the U.S. markets on Thursday, January 5, 2012.  A live conference call and webcast will be hosted by InterMune at 8:30 a.m. Eastern time that same day.  InterMune also plans to report additional efficacy and survival data from the ongoing RECAP extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF).  The company will review its plans to gain reimbursement for Esbriet across Europe and an expert in German drug reimbursement law will answer questions on the call.  Additionally, the company will update its expense guidance for 2011 and will provide forward-looking expense guidance for the full year 2012.  

Interested investors and others may participate in the conference call by dialing 888-567-5125 (U.S.) or 706-643-9223 (international), conference ID# 40200495.  To access the live webcast of the call, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available on the company's website approximately three hours after the call and will remain available until the company's next earnings call.

A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 855-859-2056 (U.S.) or 404-537-3406 (international), and entering the conference ID# 40200495. 

About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseas
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
5. InterMune to Release Third Quarter 2008 Financial Results on November 6
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune to Present at J.P. Morgan Healthcare Conference
9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 25, 2014 Continuing its award-winning ... earned three prestigious MarCom Awards for outstanding creative achievement ... a Platinum MarCom Award, the organization’s top honor, in ... St. Louis held in April of this year. The ... 14,000 attendees. Additionally, Nerium was awarded a Gold MarCom ...
(Date:11/26/2014)... DE (PRWEB) November 26, 2014 ... Heroes recognition reception on December 5, 2014, in San ... meeting. The MPN Heroes event will honor clinicians, caregivers, ... field of myeloproliferative neoplasms (MPNs). , Special guest ... discuss his family's cancer journey at the reception. ...
(Date:11/26/2014)...  Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... the detection of foodborne pathogens, today announced that Paul ... th Annual Healthcare Conference on December 2, 2014 at ... York Palace in New York, NY . ... Company, its operations, strategies and prospects may be discussed. To ...
(Date:11/24/2014)... 2014   First ... Elsevier , a world-leading provider of scientific, ... announce the launch of the latest title in the ... in Food Science . ... a new platform to keep up-to-date with the expanding volume ...
Breaking Biology Technology:Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3
... and OSLO, March 4 Pharmexa A/S and Affitech ... agreement to merge,the two companies by means of a ... Norwegian company, Affitech AS. The purpose of the merger ... vaccine business,into a company focused on the research and ...
... milestones, - Strong R&D investments, especially in EHT Dx21 and EHT ... Recruitment of 311 samples achieved for EHT Dx21, - ... Expansion of the strategic collaboration with Allergan and extension, ... of a new Management Board, - New positioning of Genomic Services ...
... highlights the importance and challenges of ... America. To move beyond the current crisis, we ... knowledge-intensive jobs, invest in "green" science and engineering ... based industries and workers. , Nanotechnologywhich some scientists ...
Cached Biology Technology:Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company 2Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company 3ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 2ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 3ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 4ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 5ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 6ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 7ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 8ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 9ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 10ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 11Nanotechnology: Will it drive a new innovation economy for the US? 2Nanotechnology: Will it drive a new innovation economy for the US? 3
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
(Date:11/21/2014)... Nov. 20, 2014   Atmel® Corporation (NASDAQ: ... (MCU) and touch technology solutions, today launched the industry,s ... with the widest V cc range from 1.7V ... and faster I 2 C bus communication speeds, and ... memory making them ideal for consumer, industrial, computer, and ...
(Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that seven officials ... least seven more will participate in the upcoming 2014 PDA ... Washington D.C. , Dec. 2-4. ... the regulatory agencies in the United States ... to help advance the use of metrics in the regulatory ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... bacteria exist as aggressive pathogens, causing diseases ranging from ... syndrome, others play a less malevolent role and some ... study, Cheryl Nickerson and her group at ASU,s Biodesign ... Van de Wiele and lead author Rosemarie De Weirdt ...
... participation in scientific research has deep roots in the ... has taken off spectacularly from launch pads across the ... communications technology and a sea change in a scientific ... Citizen science, crowd-sourced science, DIY research, volunteer monitoring, ...
... A study comparing whether endothelial colony-forming cells (ECFCs) derived from ... are more proliferative and better for forming new blood vessels ... vasculogenic., The study, carried out by researchers at the Indiana ... Cell Medicine [2(3)] and is freely available on-line ...
Cached Biology News:Beneficial bacteria may help ward off infection 2Beneficial bacteria may help ward off infection 3Beneficial bacteria may help ward off infection 4Beneficial bacteria may help ward off infection 5Inaugural cross-disciplinary Public Participation in Scientific Research conference 2Blood vessel forming potential of stem cells from human placenta and umbilical cord blood 2
IHC detection kit for PCNA in cells and tissues...
... Immunogen: Synthetic peptide derived from the ... protein. Specificity: Reacts with the ... Reactivity: Human Mouse (positive controls: WNT1-transfected ... lysates and mouse Mouse-1 cell lysates). ...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
... cAMP - [125I] Direct SPA ... SPA.Includes lysis reagents that eliminate lengthy ... cAMP measurement (optional use).Range: 1.32-84.28 ng/ml ... pmol/ml).Overnight protocol.Store at 2-8 C. Category: ...
Biology Products: